Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV003148323 | SCV003835079 | uncertain significance | Intellectual developmental disorder, X-linked, syndromic, Hackmann-Di Donato type | 2021-04-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004961224 | SCV005456427 | uncertain significance | Inborn genetic diseases | 2024-08-12 | criteria provided, single submitter | clinical testing | The c.550A>G (p.K184E) alteration is located in exon 4 (coding exon 4) of the NKAP gene. This alteration results from a A to G substitution at nucleotide position 550, causing the lysine (K) at amino acid position 184 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004750870 | SCV005364766 | uncertain significance | NKAP-related disorder | 2024-06-11 | no assertion criteria provided | clinical testing | The NKAP c.550A>G variant is predicted to result in the amino acid substitution p.Lys184Glu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0057% of alleles in individuals of African descent in gnomAD v2 (as displayed in the table above). However, in gnomAD v4 (available only on GRCh38), this variant is reported in 0.003713% of alleles in a subpopulation, including 8 homozygotes. This population data is not consistent with this variant being a primary cause of disease. Although we suspect this variant may be benign, at this time, the clinical significance is uncertain due to the absence of conclusive functional and genetic evidence. |